Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Telix Pharmaceuticals Limited (TLX) had Income from Continuous Operations of $32.93M for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$516.68M |
|
$32.93M |
|
$180.45M |
|
$336.23M |
|
$462.50M |
|
$54.18M |
|
$-17.20M |
|
$36.98M |
|
$36.98M |
|
$32.93M |
|
|
Income from Continuous Operations |
$32.93M |
$32.93M |
|
$32.93M |
|
$54.18M |
|
$59.47M |
|
331.23M |
|
345.19M |
|
$0.10 |
|
$0.10 |
|
| Balance Sheet Financials | |
$605.98M |
|
$29.65M |
|
$394.41M |
|
$1.00B |
|
$218.30M |
|
$369.41M |
|
$407.24M |
|
$625.54M |
|
$374.85M |
|
$100.33M |
|
$374.85M |
|
334.73M |
|
| Cash Flow Statement Financials | |
$28.39M |
|
$-89.17M |
|
$421.50M |
|
$81.30M |
|
$468.62M |
|
$387.32M |
|
$12.97M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.78 |
|
-- |
|
-- |
|
0.50 |
|
1.02 |
|
65.08% |
|
10.49% |
|
10.49% |
|
11.51% |
|
7.16% |
|
6.37% |
|
$18.94M |
|
-- |
|
-- |
|
-- |
|
0.52 |
|
7.17 |
|
5.62 |
|
64.99 |
|
8.79% |
|
32.82% |
|
3.29% |
|
4.42% |
|
$1.12 |
|
$0.05 |
|
$0.08 |
|